『2 Minutes with Joey - HIMS Stock News』のカバーアート

2 Minutes with Joey - HIMS Stock News

2 Minutes with Joey - HIMS Stock News

著者： 2 Minutes with Joey
無料で聴く

Two minutes with Joey on Hims & Hers (HIMS) - a quick daily recap of what the stock did today and why, in plain English. Information and entertainment only, not financial advice.Copyright 2 Minutes with Joey 社会科学
エピソード
  • HIMS Today - Jul 15: New Partners Fuel Growth

    HIMS Today - Jul 15: New Partners Fuel Growth
    2026/07/15
    Hey there! It's Joey, your friendly neighborhood investor, here to break down today’s stock action. We’re talking about Hims & Hers, and guess what? It was a green day! The stock popped up about 4.25%. Not too shabby, right?

    So, what went down? HIMS had a pretty solid day, bouncing back with some nice gains. You know how it is—some days you're riding high, and other days, it feels like you’re just trying to keep your head above water. Today, though? It was all about those gains.

    Now, why did it happen? Well, there’s a lot of buzz around Hims right now. They’ve got eight new partners on board, which is fueling their push to create this all-in-one health platform. Sounds ambitious, right? But hey, if you’re gonna dream, dream big! Also, their CEO is eyeing a heart attack prediction firm, which he thinks has "unreal" value. That’s got investors feeling optimistic. On top of that, they’re gearing up for a call on August 10 to discuss their latest health platform results. So, there’s definitely a lot of action happening behind the scenes.

    But it’s not all sunshine and rainbows. There’s some FDA scrutiny on their peptide products, and Citi just dropped a note saying there’s a “big caveat” to Amazon’s GLP-1 push that could impact HIMS. So, while things are looking good now, there are some potential bumps in the road to keep an eye on.

    So, what’s the takeaway? Hims & Hers is in the spotlight with some new partnerships and ambitious plans, but they’ve got some challenges ahead too. Just a friendly reminder that the market can be wild, so always keep that in mind!

    Alright, that’s a wrap for today! Just here to keep you in the loop, so remember, this isn’t financial advice—just some friendly info. Catch you later!
    続きを読む 一部表示
    2 分
  • HIMS Today - Jul 14: Amazon's GLP-1 War Hits HIMS

    HIMS Today - Jul 14: Amazon's GLP-1 War Hits HIMS
    2026/07/14
    Hey, what’s up? It’s Joey here, your friendly neighborhood investor breaking down today’s market moves. Let’s talk about Hims & Hers, or HIMS for short. Today was a bit of a rough ride; the stock was down about 1.19%.

    So, what happened? Well, it looks like HIMS got a little smoked after some news about Amazon ramping up its GLP-1 competition with Ozempic. Yeah, that one stung. Investors were clearly worried about how that might affect HIMS' growth, especially since they’re all about health and wellness products. When big players like Amazon step into the ring, it can get a bit dicey for smaller companies.

    Now, why did people hit the sell button so fast? There’s been chatter around the whole AI healthcare scene, and with earnings calls coming up, folks are on high alert. HIMS is set to drop their Q2 results on August 10, and everyone’s trying to figure out if they’ll impress or flop. Plus, there was some buzz about insider share sales, which usually raises eyebrows. It’s like a little red flag that makes people think twice before holding onto their shares.

    On a brighter note, HIMS did schedule that call to discuss their latest health platform results, which could be a big deal. If they have good stuff to share, it might just turn the tide for them. Just keep an eye on that.

    So yeah, that’s the scoop on HIMS today. It was a tough day, but these things happen in the market. Remember, I’m just here to share what’s happening, not to give any financial advice. Catch you later!
    続きを読む 一部表示
    1 分
  • HIMS Today - Jul 13: New Partners, FDA Meeting Buzz

    HIMS Today - Jul 13: New Partners, FDA Meeting Buzz
    2026/07/13
    Hey, what’s up? It’s Joey here, your go-to guy for stock chatter. I’ve been investing for a while, and today we’re talking about Hims & Hers, or HIMS for short. It was a bit of a mixed bag today, barely up by about a third of a percent. Not a big move, but hey, at least it wasn’t a total flop.

    So, what went down? HIMS is trying to shake things up with eight new partnerships, aiming to build this all-in-one health platform. Sounds cool, right? But here’s the kicker: they just had their worst week in two months. Ouch. They’re also gearing up for a big FDA meeting about their peptides campaign, which could be a game-changer for them.

    Now, why the mixed vibes? Well, on one hand, those new partnerships are exciting and could signal growth, but on the flip side, there’s chatter about whether their GLP-1 strategy has backfired. That’s a fancy way of saying they might have bet on the wrong horse. Investors are probably feeling a bit jittery with all this back-and-forth.

    And just to keep it real, the volume today was way off compared to their average. Like, they only had about 1.6 million shares traded when they usually see over 16 million. That tells me people might be sitting on the sidelines, waiting to see how this FDA meeting goes.

    One thing worth keeping an eye on is that potential rally buzz. Some fund managers are saying HIMS could rally up to 60% this week if the stars align. I mean, that sounds great, but let’s keep those expectations in check, yeah?

    So, to wrap it up, HIMS is in a bit of a tug-of-war between new opportunities and some challenges. It’s definitely a wait-and-see moment. Just remember, this is all for info and fun, not financial advice. Catch you later!
    続きを読む 一部表示
    2 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません